Axcan Takes Third Stab At FDA Approval For Helizide
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm said it could launch the H. pylori bacteria agent in the first half of 2007.
You may also be interested in...
Axcan’s Pylera Clears FDA; Third Name’s The Charm
Oft-delayed H. pylori treatment will enter $160 mil. U.S. market in 2007.
Axcan’s Pylera Clears FDA; Third Name’s The Charm
Oft-delayed H. pylori treatment will enter $160 mil. U.S. market in 2007.
Axcan To Ax Itax?: Phase III Data Put Functional Dyspepsia Program In Jeopardy
Firm awaits further analysis of international study and second Phase III trial data due by June before pulling plug; diabetic gastropathy program to continue.